Biochemistry-first molecular monograph · Version 5.0 · Updated 23 August 2026
Semax
ACTH-derived neuroactive signalling and route-bound evidence
Intranasal Semax changes BDNF/TrkB-associated biology in animals and produces acute measurable human connectivity effects.
This monograph evaluates Semax as the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro. It maps ACTH-derived identity, BDNF/TrkB biology, ischemia models and limited intranasal human neurophysiology without transferring those findings to injection.
This monograph begins with the molecule and follows the causal chain through biochemistry, cellular mechanism, exposure and integrated physiology. Population studies enter only at the terminal stress-test: useful for the proposition actually tested, incapable of defining the molecule or replacing the causal model.
Epistemological position
The causal chain carries the science.
Identity establishes what exists. Biochemistry establishes what can react. Pharmacology establishes whether the reaction is reachable. Physiology establishes what the system does with it. Statistical human observation comes last and adjudicates only the route, exposure, population and outcome actually studied.
A population average cannot identify a molecule, create a mechanism or decide an individual response. A demonstrated mechanism remains bounded by the causal step shown; a terminal study can confirm or refute its translation under specified conditions, never rewrite the underlying chemistry.
Molecular dossier
The entity before the outcome.
- ENTITY
- Met-Glu-His-Phe-Pro-Gly-Pro, an ACTH(4–7)-related heptapeptide
- BIOCHEMICAL CLASS
- Neuroactive melanocortin-derived peptide analogue
- PRIMARY SYSTEM
- BDNF/TrkB · neuroimmune transcription · acute network connectivity
- IDENTITY BOUNDARY
- Semax is neither ACTH nor ‘Samax’. Intranasal evidence cannot establish injectable exposure, and an acute neural signal cannot be relabelled as clinical neuroprotection.
Action ledger
Describe the action before judging its value.
Benefit is a downstream clinical judgement. The scientific object is the action itself: what moves, under which exposure, in which biological state, and where the inference stops.
Attributed biochemical action
Intranasal Semax changes BDNF/TrkB-associated biology in animals and produces acute measurable human connectivity effects.
Exposure and reachability
Human neurophysiological and clinical reports are predominantly intranasal. They cannot be transferred automatically to an injectable route.
Physiological direction is contextual
BDNF/TrkB signalling, neuroimmune transcription and network connectivity are state- and time-dependent. Their meaning differs between acute ischaemia, recovery, fatigue and an otherwise healthy brain. A neurophysiological response establishes that the system moved; durable cognition or neurological function requires a coherent downstream trajectory, not merely a larger biomarker signal.
Individual adjudication boundary
Human PK and independent trials connecting molecular or imaging target engagement to durable patient-important function. BDNF movement, transcriptomic change or fMRI connectivity does not by itself prove cognition enhancement, stroke recovery or systemic regeneration.
Causal map with terminal adjudication
The scientific hierarchy is explicit.
I–II developed preclinically; III partial for intranasal human neurophysiology
Intranasal Semax changes BDNF/TrkB-associated biology in animals and produces acute measurable human connectivity effects.
Class C/D in limited intranasal neurological reports; E for parenteral claims
This descriptor applies only to the named route, population and outcome. It neither ranks nor creates the molecule’s biochemical science.
Translation boundary
Human PK and independent trials connecting molecular or imaging target engagement to durable patient-important function.
What must not be inferred
BDNF movement, transcriptomic change or fMRI connectivity does not by itself prove cognition enhancement, stroke recovery or systemic regeneration.
Historical and international corpus
Old research is not absent research.
Semax is a Soviet/Russian ACTH-fragment analogue studied since at least the late 1980s, with human stroke publications from the 1990s onward. It is not a century-old exact entity, but it has a much deeper translational history than a contemporary English-only review suggests.
The Russian corpus must be integrated with its original route, dose, treatment-era context and methods. Historical use is neither proof by longevity nor grounds for deletion.
ACTH(4–7)-PGP experimental programme predates modern indexing habits
A Russian primary experiment reported dose-specific effects of ACTH(4–7)-PGP on spatial learning. This establishes that the exact sequence lineage was under experimental study decades before recent transcriptomic and imaging papers.[7]
Early Russian human neuroprotection programme
Clinical publications examined acute ischaemic stroke and post-hypoxic encephalopathy, including dose, neurological and electrophysiological observations. Their historical comparators and reporting standards limit modern effect estimation, but they are direct human evidence and must remain in the map.[8][9][10]
Mechanistic and biochemical calculus
Constraint, measurement and inference are not the same claim.
A biochemical proposition can be powerful without a clinical trial, but its premises, exposure and domain must remain explicit. Each statement below is labelled by the operation that supports it.
ACTH ancestry does not imply ACTH endocrine action
Semax retains a short ACTH-derived core and adds Pro-Gly-Pro but lacks the full hormone. Sequence relationship supports design provenance, not automatic melanocortin or adrenal equivalence.[1][7]
Multiple molecular layers converge after nasal exposure
BDNF protein, TrkB phosphorylation, neuroimmune transcripts and acute connectivity changes have been measured in different systems. Convergence strengthens biological activity while leaving the proximal binding target incompletely resolved.[1][2][4][5][6]
Historical clinical signal needs a modern counterfactual
A treatment-era improvement cannot be transported unchanged into present stroke pathways. Contemporary reperfusion, imaging, rehabilitation and prespecified functional outcomes define a different causal comparison.[3][8][9][10]
Complete scientific web editionOpen the full causal analysis and referencesThe decision-grade summary remains above. The complete publication stays available here and as a downloadable PDF.
Causal architecture
From molecular event to organismal hypothesis.
Ischaemia recruits neuroimmune networks
Experimental focal ischaemia produces Semax-associated changes in cytokine, immune-response and stress programmes. Such a time-sensitive injury environment cannot be equated with fatigue, attention or cognition in a non-ischaemic brain.[5]
What is established
✓ Exact heptapeptide sequence
✓ BDNF/TrkB preclinical signals
✓ Intranasal human neurophysiology
What remains unresolved
? Controlled contemporary efficacy
? Injectable PK and outcomes
? Long-term safety
Causal hierarchy
Seven evidentiary layers. No category substitution.
Levels I-V build the causal and translational model. Human observations and controlled clinical trials then test the complete proposition under the route, exposure, population and outcome actually studied. A trial is terminal adjudication, not the source of molecular truth.
IMolecular identity and chemistryWhat exact sequence, terminal chemistry, formulation and route exist?
IIBiochemistry and target architectureWhat reactions, binding events and signalling steps are physically possible?
IIICells and ex-vivo tissuesWhat changes in the relevant cell or isolated tissue system?
IVAnimal and in-vivo pharmacologyDoes exposure reach the mechanism in an integrated organism?
VIntegrated physiology and translationHow do tissue state, feedback, dose and individual terrain alter the response?
VIHuman PK and observational signalIs the entity present, tolerated and associated with a signal in humans?
VIIControlled clinical trialsDoes the specified protocol change a prespecified patient-relevant outcome?
Method applied to Semax
Where this molecule’s evidence can, and cannot, travel.
The complete corpus-wide attribution rules are published in the scientific methodology. This is their molecule-specific application.
Entity rule applied
Semax is neither ACTH nor ‘Samax’. Intranasal evidence cannot establish injectable exposure, and an acute neural signal cannot be relabelled as clinical neuroprotection.
Reachability rule applied
Human neurophysiological and clinical reports are predominantly intranasal. They cannot be transferred automatically to an injectable route. The decisive exposure boundary for Semax therefore remains molecule-, formulation- and route-specific.
Causal-strength rule applied
Intranasal Semax changes BDNF/TrkB-associated biology in animals and produces acute measurable human connectivity effects. This places the present causal depth at i–ii developed preclinically; iii partial for intranasal human neurophysiology. That grade describes which links in the mechanism have been demonstrated; it is not a consumer rating and cannot be converted into a general promise of benefit.
Human-adjudication rule applied
Class C/D in limited intranasal neurological reports; E for parenteral claims. This terminal descriptor answers only the population, route, exposure and outcome actually observed; it neither upgrades nor cancels a different link in Semax’s causal chain.
Translation rule applied
Human PK and independent trials connecting molecular or imaging target engagement to durable patient-important function. BDNF movement, transcriptomic change or fMRI connectivity does not by itself prove cognition enhancement, stroke recovery or systemic regeneration.
Falsification rule applied
The interpretation must change if any of its decisive propositions fail. For Semax, the predeclared tests are: Failure to reproduce BDNF/TrkB movement with authenticated material would weaken the neurotrophic model. No route-specific human exposure would undermine pharmacological interpretation of intranasal dosing. Connectivity change without durable function would falsify imaging-as-clinical-benefit inference. These are active boundaries on the conclusion, not research questions appended after a favourable narrative.
Foundational synthesis
Molecular identity and entity resolution
Semax is the defined heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, derived from an ACTH(4–7) motif with a Pro-Gly-Pro extension. It is not ‘Samax’ and it is not a combination.
Foundational synthesis
Biochemical mechanism and target architecture
Preclinical studies report BDNF/TrkB and neuroplasticity-related changes. Network or molecular modulation is target engagement, not proof of cognitive or clinical benefit.
Foundational synthesis
In-vivo pharmacology and exposure
Human neurophysiological and clinical reports are predominantly intranasal. They cannot be transferred automatically to an injectable route.
Foundational synthesis
Integrated physiology and individual terrain
BDNF/TrkB signalling, neuroimmune transcription and network connectivity are state- and time-dependent. Their meaning differs between acute ischaemia, recovery, fatigue and an otherwise healthy brain. A neurophysiological response establishes that the system moved; durable cognition or neurological function requires a coherent downstream trajectory, not merely a larger biomarker signal.
Foundational synthesis
Terminal human stress-test
A small resting-state fMRI study included 24 healthy participants and reported network-level change. Small or methodologically limited stroke cohorts have reported clinical signals in treatment contexts that require comparison with modern stroke care.
Foundational synthesis
Counterevidence and causal boundaries
Imaging change does not establish cognitive benefit, and historical non-equivalent controls do not support a universal neuroprotection claim. Long-term and injectable safety remain unresolved.
Foundational synthesis
Scientific conclusion
Semax has defined molecular identity, biologically coherent preclinical evidence and limited intranasal human signals. Route, endpoint and contemporary comparator define what may be inferred.
Extended analysis
Molecular identity
Semax is Met-Glu-His-Phe-Pro-Gly-Pro: an ACTH(4-7)-related tetrapeptide extended by Pro-Gly-Pro. It is not Samax, not ACTH, and not a mixture. The extension and absence of the full ACTH sequence are central to its distinct endocrine and neuroactive profile.[1][2]
Most human work uses intranasal administration. Animal mechanistic studies also commonly use intranasal exposure. This creates a more coherent route chain than exists for injectable use, but human nasal PK and tissue exposure remain incompletely characterised.[1][2][3]
Extended analysis
BDNF and TrkB programme
In rat hippocampus, a single intranasal dose increased BDNF protein, TrkB phosphorylation and selected BDNF and TrkB transcripts. The experiment also reported improved conditioned avoidance behaviour. This connects molecular signalling with a behavioural endpoint in the same species.[1]
Separate rat basal-forebrain work identified specific, reversible binding and increased BDNF after intranasal administration. These findings support a neurotrophic mechanism while leaving the proximal human molecular target and therapeutic exposure-response unresolved.[4]
Extended analysis
Ischemia and neuroimmune mechanisms
Rodent focal-ischemia transcriptomics found that Semax changed immune-response, cytokine, stress-response and ribosomal gene programmes. The data suggest that neuroprotection, where present, may involve neuroimmune coordination rather than one isolated trophic pathway.[5]
An ischemia model creates a particular time-sensitive biological environment. Mechanisms observed after experimental occlusion cannot be assumed to improve cognition, fatigue or attention in a healthy brain.[5]
Extended analysis
Human neuroimaging
A small resting-state fMRI study included 24 healthy participants, with 14 receiving intranasal Semax and 10 placebo. The investigators reported changes in the rostral default-mode-network subcomponent minutes after administration.[2]
A larger connectomic experiment comparing Selank, Semax and placebo reported acute functional-connectivity changes involving amygdala-temporal networks. These are target-engagement-like neurophysiological signals, not direct evidence of memory improvement or stroke recovery.[6]
Extended analysis
Clinical stroke literature
Historical clinical reports have described neurological signals when Semax was added in stroke care. Accessible reports are small, often incompletely described and embedded in treatment contexts that may not match modern reperfusion, imaging and rehabilitation standards.[3]
A contemporary claim requires a contemporary comparator. A signal against historical or non-equivalent care cannot define incremental benefit alongside current thrombolysis, thrombectomy, antithrombotic management and structured rehabilitation.[3]
Extended analysis
Translation boundary
Semax has a defined molecule, biologically coherent preclinical evidence and measurable acute intranasal human neurophysiology. It lacks a mature, independently replicated clinical programme with route-specific PK, prespecified patient-important endpoints and long-term safety.[1][2][3][6]
Imaging change, BDNF movement and transcriptomic response each demonstrate a level of biology. None alone establishes broad nootropic or neuroprotective efficacy. Injectable use would require a separate evidence chain beginning with exposure.[1][2][5]
Evidence atlas
Every claim keeps its experimental address.
12 claim units are mapped to their evidentiary layer, experimental frame and source records. The layer describes what the evidence can answer; it is not a popularity score.
| Layer | Experimental frame | Finding and boundary | Sources |
|---|---|---|---|
| IMolecular identity | Molecular identity · claim 1 | Semax is Met-Glu-His-Phe-Pro-Gly-Pro: an ACTH(4-7)-related tetrapeptide extended by Pro-Gly-Pro. It is not Samax, not ACTH, and not a mixture. The extension and absence of the full ACTH sequence are central to its distinct endocrine and neuroactive profile. | [1][2] |
| IMolecular identity | Molecular identity · claim 2 | Most human work uses intranasal administration. Animal mechanistic studies also commonly use intranasal exposure. This creates a more coherent route chain than exists for injectable use, but human nasal PK and tissue exposure remain incompletely characterised. | [1][2][3] |
| IVIntegrated in-vivo model | BDNF and TrkB programme · claim 1 | In rat hippocampus, a single intranasal dose increased BDNF protein, TrkB phosphorylation and selected BDNF and TrkB transcripts. The experiment also reported improved conditioned avoidance behaviour. This connects molecular signalling with a behavioural endpoint in the same species. | [1] |
| VIHuman exposure or signal | BDNF and TrkB programme · claim 2 | Separate rat basal-forebrain work identified specific, reversible binding and increased BDNF after intranasal administration. These findings support a neurotrophic mechanism while leaving the proximal human molecular target and therapeutic exposure-response unresolved. | [4] |
| IVIntegrated in-vivo model | Ischemia and neuroimmune mechanisms · claim 1 | Rodent focal-ischemia transcriptomics found that Semax changed immune-response, cytokine, stress-response and ribosomal gene programmes. The data suggest that neuroprotection, where present, may involve neuroimmune coordination rather than one isolated trophic pathway. | [5] |
| II/VMechanism and physiological translation | Ischemia and neuroimmune mechanisms · claim 2 | An ischemia model creates a particular time-sensitive biological environment. Mechanisms observed after experimental occlusion cannot be assumed to improve cognition, fatigue or attention in a healthy brain. | [5] |
| VIHuman exposure or signal | Human neuroimaging · claim 1 | A small resting-state fMRI study included 24 healthy participants, with 14 receiving intranasal Semax and 10 placebo. The investigators reported changes in the rostral default-mode-network subcomponent minutes after administration. | [2] |
| VIHuman exposure or signal | Human neuroimaging · claim 2 | A larger connectomic experiment comparing Selank, Semax and placebo reported acute functional-connectivity changes involving amygdala-temporal networks. These are target-engagement-like neurophysiological signals, not direct evidence of memory improvement or stroke recovery. | [6] |
| IVIntegrated in-vivo model | Clinical stroke literature · claim 1 | Historical clinical reports have described neurological signals when Semax was added in stroke care. Accessible reports are small, often incompletely described and embedded in treatment contexts that may not match modern reperfusion, imaging and rehabilitation standards. | [3] |
| IVIntegrated in-vivo model | Clinical stroke literature · claim 2 | A contemporary claim requires a contemporary comparator. A signal against historical or non-equivalent care cannot define incremental benefit alongside current thrombolysis, thrombectomy, antithrombotic management and structured rehabilitation. | [3] |
| VIHuman exposure or signal | Translation boundary · claim 1 | Semax has a defined molecule, biologically coherent preclinical evidence and measurable acute intranasal human neurophysiology. It lacks a mature, independently replicated clinical programme with route-specific PK, prespecified patient-important endpoints and long-term safety. | [1][2][3][6] |
| VIHuman exposure or signal | Translation boundary · claim 2 | Imaging change, BDNF movement and transcriptomic response each demonstrate a level of biology. None alone establishes broad nootropic or neuroprotective efficacy. Injectable use would require a separate evidence chain beginning with exposure. | [1][2][5] |
Methods and coverage
A reproducible boundary, not an implied exhaustive review.
This is a curated mechanistic monograph built from primary records. It does not claim systematic-review completeness. Absence of a retrieved result is not evidence that an effect is absent.
- SEARCH SURFACE
- PubMed/MEDLINE primary records, Russian-language indexed abstracts, and reference-chaining for entity-defining, historical and translational studies. Language, geography, regulatory status and journal fashion are not evidence grades.
- QUERY FRAME
- Semax · ACTH(4-7) · Met-Glu-His-Phe-Pro-Gly-Pro · BDNF · TrkB · intranasal · stroke · functional connectivity
- EVIDENCE CUTOFF
- 23 August 2026
- ENTITY EXCLUSION
- Semax is neither ACTH nor ‘Samax’. Intranasal evidence cannot establish injectable exposure, and an acute neural signal cannot be relabelled as clinical neuroprotection.
- TRACEABILITY
- 12 extended claim units plus 2 historical records and 3 mechanistic-calculus records; 10 cited records in the complete corpus.
- INTERPRETIVE RULE
- Identity → physical constraint → measured reaction or binding → reachable exposure → system response → outcome. Statistical significance does not manufacture mechanism; mechanistic plausibility does not manufacture a patient outcome.
Falsification map
What could make the proposition wrong?
A scientific monograph must state not only why a mechanism may hold, but what observation would weaken or overturn the inference.
- 01Failure to reproduce BDNF/TrkB movement with authenticated material would weaken the neurotrophic model.
- 02No route-specific human exposure would undermine pharmacological interpretation of intranasal dosing.
- 03Connectivity change without durable function would falsify imaging-as-clinical-benefit inference.
Research agenda
What would materially change the conclusion?
A useful research agenda resolves the weakest link in the identity-to-outcome chain. It does not merely add more observations of the same type.
- 01Human intranasal PK and tissue-exposure studies
- 02Modern controlled stroke adjunct trials
- 03Cognition trials with prespecified functional endpoints
- 04Independent replication of imaging findings
- 05Long-term nasal tolerability
- 06Separate injectable PK before parenteral claims
Cited primary evidence corpus
10 source records used in this publication.
Reference numbers resolve directly to indexed records. This corpus documents the claims made here; it is not presented as an exhaustive systematic-review search. Index access does not upgrade the evidentiary class of a study.
- [1]Dolotov et al. Brain Res. 2006;1117:54–60.PMID 16996037 ↗
- [2]Lebedeva et al. Bull Exp Biol Med. 2018;165:653–656.PMID 30225715 ↗
- [3]Gusev et al. Zh Nevrol Psikhiatr. 2018;118:61–68.PMID 29798983 ↗
- [4]Dolotov et al. Semax binding and BDNF increase in rat basal forebrain. J Neurochem. 2006.PMID 16635254 ↗
- [5]Dmitrieva et al. Semax regulates immune-response genes during ischemic brain injury in rats. BMC Genomics. 2017.PMID 28255762 ↗
- [6]Panikratova et al. Functional connectomic approach to Selank and Semax effects. Dokl Biol Sci. 2020.PMID 32342318 ↗
- [7]Chepurnova et al. ACTH(4-7)-PGP and spatial learning in rats. Fiziol Zh SSSR. 1989. Russian-language primary study.PMID 2548895 ↗
- [8]Miasoedova et al. Mechanisms of Semax neuroprotection in acute ischaemic stroke. Zh Nevrol Psikhiatr. 1999. Russian-language comparative study.PMID 10358912 ↗
- [9]Alekseeva et al. Semax in post-hypoxic encephalopathy follow-up. Anesteziol Reanimatol. 1999. Russian-language comparative study.PMID 10199046 ↗
- [10]Skvortsova et al. Semax in acute hemispheric ischaemic stroke: clinical and electrophysiological study. Zh Nevrol Psikhiatr. 2001.PMID 11517472 ↗
Permanent citation
Cite this publication
Wibowo V. Semax: Biochemical, Mechanistic and Physiological Monograph. Clinic Terrain Clinical Intelligence Unit. Version 5.0. Updated 23 August 2026.
https://www.clinicterrain.com/research/peptides/semaxPublication and reference-verification method →Authorship and accountability
Valentine Wibowo, Clinical Researcher, Clinic Terrain Clinical Intelligence Unit, performed the conceptualisation, evidence synthesis, scientific interpretation and drafting. dr. I Wayan Cahyadi Surya Distira Putra, MPH completed medical review and approved the publication. Internal medical review is not represented as independent peer review.
No new patient data or human research were undertaken. The author and reviewer declare no personal financial competing interests. Clinic Terrain and Klinik Pratama Cepat Sehat provide clinical services; that institutional relationship is disclosed.